Generation of Human Pluripotent Stem Cell-derived Endothelial Cells and Their Therapeutic Utility

Shin Jeong Lee, Kyung Hee Kim, Youngsup Yoon

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Purpose of Review: Human pluripotent stem cell-derived endothelial cells (hPSC-ECs) emerged as an important source of cells for cardiovascular regeneration. This review summarizes protocols for generating hPSC-ECs and provides an overview of the current state of the research in clinical application of hPSC-derived ECs. Recent Findings: Various systems were developed for differentiating hPSCs into the EC lineage. Stepwise two-dimensional systems are now well established, in which various growth factors, small molecules, and coating materials are used at specific developmental stages. Moreover, studies made significant advances in clinical applicability of hPSC-ECs by removing undefined components from the differentiation system, improving the differentiation efficiency, and proving their direct vascular incorporating effects, which contrast with adult stem cells and their therapeutic effects in vivo. Finally, by using biomaterial-mediated delivery, investigators improved the survival of hPSC-ECs to more than 10 months in ischemic tissues and described long-term behavior and safety of in vivo transplanted hPSC-ECs at the histological level. Summary: hPSC-derived ECs can be as a critical source of cells for treating advanced cardiovascular diseases. Over the past two decades, substantial improvement has been made in the differentiation systems and their clinical compatibility. In the near future, establishment of fully defined differentiation systems and proof of the advantages of biomaterial-mediated cell delivery, with some additional pre-clinical studies, will move this therapy into a vital option for treating those diseases that cannot be managed by currently available therapies.

Original languageEnglish
Article number45
JournalCurrent Cardiology Reports
Volume20
Issue number6
DOIs
Publication statusPublished - 2018 Jun 1

Fingerprint

Pluripotent Stem Cells
Endothelial Cells
Biocompatible Materials
Therapeutics
Adult Stem Cells
Therapeutic Uses
Blood Vessels
Regeneration
Intercellular Signaling Peptides and Proteins
Cardiovascular Diseases
Research Personnel
Safety
Survival
Research

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{d77da99e9abe4fb38d500f2c7f47e002,
title = "Generation of Human Pluripotent Stem Cell-derived Endothelial Cells and Their Therapeutic Utility",
abstract = "Purpose of Review: Human pluripotent stem cell-derived endothelial cells (hPSC-ECs) emerged as an important source of cells for cardiovascular regeneration. This review summarizes protocols for generating hPSC-ECs and provides an overview of the current state of the research in clinical application of hPSC-derived ECs. Recent Findings: Various systems were developed for differentiating hPSCs into the EC lineage. Stepwise two-dimensional systems are now well established, in which various growth factors, small molecules, and coating materials are used at specific developmental stages. Moreover, studies made significant advances in clinical applicability of hPSC-ECs by removing undefined components from the differentiation system, improving the differentiation efficiency, and proving their direct vascular incorporating effects, which contrast with adult stem cells and their therapeutic effects in vivo. Finally, by using biomaterial-mediated delivery, investigators improved the survival of hPSC-ECs to more than 10 months in ischemic tissues and described long-term behavior and safety of in vivo transplanted hPSC-ECs at the histological level. Summary: hPSC-derived ECs can be as a critical source of cells for treating advanced cardiovascular diseases. Over the past two decades, substantial improvement has been made in the differentiation systems and their clinical compatibility. In the near future, establishment of fully defined differentiation systems and proof of the advantages of biomaterial-mediated cell delivery, with some additional pre-clinical studies, will move this therapy into a vital option for treating those diseases that cannot be managed by currently available therapies.",
author = "Lee, {Shin Jeong} and Kim, {Kyung Hee} and Youngsup Yoon",
year = "2018",
month = "6",
day = "1",
doi = "10.1007/s11886-018-0985-8",
language = "English",
volume = "20",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "6",

}

Generation of Human Pluripotent Stem Cell-derived Endothelial Cells and Their Therapeutic Utility. / Lee, Shin Jeong; Kim, Kyung Hee; Yoon, Youngsup.

In: Current Cardiology Reports, Vol. 20, No. 6, 45, 01.06.2018.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Generation of Human Pluripotent Stem Cell-derived Endothelial Cells and Their Therapeutic Utility

AU - Lee, Shin Jeong

AU - Kim, Kyung Hee

AU - Yoon, Youngsup

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Purpose of Review: Human pluripotent stem cell-derived endothelial cells (hPSC-ECs) emerged as an important source of cells for cardiovascular regeneration. This review summarizes protocols for generating hPSC-ECs and provides an overview of the current state of the research in clinical application of hPSC-derived ECs. Recent Findings: Various systems were developed for differentiating hPSCs into the EC lineage. Stepwise two-dimensional systems are now well established, in which various growth factors, small molecules, and coating materials are used at specific developmental stages. Moreover, studies made significant advances in clinical applicability of hPSC-ECs by removing undefined components from the differentiation system, improving the differentiation efficiency, and proving their direct vascular incorporating effects, which contrast with adult stem cells and their therapeutic effects in vivo. Finally, by using biomaterial-mediated delivery, investigators improved the survival of hPSC-ECs to more than 10 months in ischemic tissues and described long-term behavior and safety of in vivo transplanted hPSC-ECs at the histological level. Summary: hPSC-derived ECs can be as a critical source of cells for treating advanced cardiovascular diseases. Over the past two decades, substantial improvement has been made in the differentiation systems and their clinical compatibility. In the near future, establishment of fully defined differentiation systems and proof of the advantages of biomaterial-mediated cell delivery, with some additional pre-clinical studies, will move this therapy into a vital option for treating those diseases that cannot be managed by currently available therapies.

AB - Purpose of Review: Human pluripotent stem cell-derived endothelial cells (hPSC-ECs) emerged as an important source of cells for cardiovascular regeneration. This review summarizes protocols for generating hPSC-ECs and provides an overview of the current state of the research in clinical application of hPSC-derived ECs. Recent Findings: Various systems were developed for differentiating hPSCs into the EC lineage. Stepwise two-dimensional systems are now well established, in which various growth factors, small molecules, and coating materials are used at specific developmental stages. Moreover, studies made significant advances in clinical applicability of hPSC-ECs by removing undefined components from the differentiation system, improving the differentiation efficiency, and proving their direct vascular incorporating effects, which contrast with adult stem cells and their therapeutic effects in vivo. Finally, by using biomaterial-mediated delivery, investigators improved the survival of hPSC-ECs to more than 10 months in ischemic tissues and described long-term behavior and safety of in vivo transplanted hPSC-ECs at the histological level. Summary: hPSC-derived ECs can be as a critical source of cells for treating advanced cardiovascular diseases. Over the past two decades, substantial improvement has been made in the differentiation systems and their clinical compatibility. In the near future, establishment of fully defined differentiation systems and proof of the advantages of biomaterial-mediated cell delivery, with some additional pre-clinical studies, will move this therapy into a vital option for treating those diseases that cannot be managed by currently available therapies.

UR - http://www.scopus.com/inward/record.url?scp=85046480848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046480848&partnerID=8YFLogxK

U2 - 10.1007/s11886-018-0985-8

DO - 10.1007/s11886-018-0985-8

M3 - Review article

C2 - 29730842

AN - SCOPUS:85046480848

VL - 20

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 6

M1 - 45

ER -